Immuno-Oncology | Specialty

Novel Peptide Vaccine Safe, Effective in High-Risk Breast Cancer

September 6th 2014

A novel HER2-derived peptide vaccine designed to stimulate CD8+ cytotoxic T-lymphocytes reduced the rate of breast cancer recurrence and proved safe and well tolerated in the adjuvant setting.

Bristol-Myers Squibb Challenges Patent on Merck's Pembrolizumab

September 5th 2014

BMS has filed a lawsuit over Merck's newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?

September 5th 2014

This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.

FDA Approves Pembrolizumab for Advanced Melanoma

September 4th 2014

The FDA has approved pembrolizumab (Keytruda) as a treatment for patients with advanced or unresectable melanoma who are no longer responding to other drugs, making it the first PD-1 inhibitor to gain approval in the United States.

Enzalutamide + Sipuleucel-T Gives Immune Boost in mCRPC

September 1st 2014

Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.

Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study

August 30th 2014

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond

August 29th 2014

Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.

Dr. Rizvi Discusses Pembrolizumab for Non-Small Cell Lung Cancer

August 29th 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity

August 28th 2014

Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.

Pembrolizumab Combination Study Planned in Prostate Cancer

August 27th 2014

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder Cancer

August 27th 2014

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

Pharma Collaborations Abound Across Oncology

August 21st 2014

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Dr. Herbst Discusses New Immunotherapy Agents for Lung Cancer

August 20th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.

Ludwig Researchers Focus on a New Set of Immune Checkpoints

August 5th 2014

Ever since ipilimumab (Yervoy) gained FDA approval in 2011 for the treatment of metastatic melanoma, the immune checkpoint blockade strategy that the agent employs has been an intense focus of interest in research and pharmaceutical circles.

James Allison Discusses the Potentiation of Checkpoint Blockage with Oncolytic Viruses

August 5th 2014

James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.

Herbst Tackles Key Questions in Emerging PD-1/PD-L1 Immunotherapy for NSCLC

August 2nd 2014

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.

Dr. Papadimitrakopoulou Discusses the Lung-MAP Trial

August 2nd 2014

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial, which uses next-generation sequencing as a screening test rather than screening for one mutation.

Dr. Ramalingam Discusses the Utility of Tecemotide in NSCLC

August 1st 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the utility of the vaccine tecemotide as treatment for non-small cell lung cancer.

Immunotherapy Advances in Melanoma

July 28th 2014

Melanoma care has fortunately undergone a whirlwind of changes over the past several years. Novel immunotherapies are perhaps the most exciting recent development in cancer care because patients can enjoy long-term benefit from these treatments, meaning that they are possibly "cured."

Frontline Nivolumab Leads to Early, Durable Responses in NSCLC

July 25th 2014

One-third (30%) of chemotherapy-naïve non–small cell lung cancer (NSCLC) patients treated with nivolumab, an anti-PD-1 immune checkpoint antibody, responded to treatment in a phase I study.

NEXT PAGE
PREVIOUS PAGE